# Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

> **NCT01814813** · PHASE2 · TERMINATED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 90 (actual)

## Conditions studied

- Recurrent Glioblastoma
- Recurrent Adult Brain Tumor
- Gliosarcoma

## Interventions

- **BIOLOGICAL:** HSPPC-96
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT01814813
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06-19
- **Primary completion:** 2017-04-03
- **Final completion:** 2023-05-22
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** DSMB futility analysis
- **Last updated:** 2025-01-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01814813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01814813, "Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01814813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*